Skip to Content

Enveric Biosciences Inc ENVB

Morningstar Rating
$1.66 +0.21 (14.48%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ENVB is trading at a 67% discount.
Price
$1.67
Fair Value
$1.11
Uncertainty
Extreme
1-Star Price
$87.56
5-Star Price
$2.88
Economic Moat
Fmhn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ENVB is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.45
Day Range
$1.451.90
52-Week Range
$0.656.98
Bid/Ask
$1.65 / $1.67
Market Cap
$4.55 Mil
Volume/Avg
13.8 Mil / 3.9 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
26

Valuation

Metric
ENVB
Price/Earnings (Normalized)
Price/Book Value
1.49
Price/Sales
Price/Cash Flow
Price/Earnings
ENVB

Financial Strength

Metric
ENVB
Quick Ratio
1.02
Current Ratio
1.39
Interest Coverage
Quick Ratio
ENVB

Profitability

Metric
ENVB
Return on Assets (Normalized)
−91.13%
Return on Equity (Normalized)
−136.43%
Return on Invested Capital (Normalized)
−129.75%
Return on Assets
ENVB
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRThlz$550.4 Bil
VRTX
Vertex Pharmaceuticals IncYlmwgh$111.8 Bil
REGN
Regeneron Pharmaceuticals IncLpmsvcv$107.9 Bil
MRNA
Moderna IncCvrg$36.3 Bil
ARGX
argenx SE ADRDhkcy$23.0 Bil
BNTX
BioNTech SE ADRGzmjl$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncKrbfb$19.2 Bil
BMRN
Biomarin Pharmaceutical IncNzygqbk$16.4 Bil
RPRX
Royalty Pharma PLC Class AJlhpvcx$13.4 Bil
INCY
Incyte CorpZsjbsd$13.3 Bil

Sponsor Center